Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacteriumulcerans disease, a protocol for a randomised controlled trial in Ghana. (2022)
Attributed to:
R Phillips, KNUST Ghana. Pathogenesis and management of M. ulcerans disease, Buruli ulcer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3310/nihropenres.13332.1
PubMed Identifier: 36825217
Publication URI: http://europepmc.org/abstract/MED/36825217
Type: Journal Article/Review
Volume: 2
Parent Publication: NIHR open research
ISSN: 2633-4402